Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Pharmacy
Published in: International Journal of Clinical Pharmacy 4/2012

01-08-2012 | Commentary

Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?

Authors: Ines Krass, Adrian T. Walker, Gerald F. Watts

Published in: International Journal of Clinical Pharmacy | Issue 4/2012

Login to get access

Abstract

Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. It is estimated that there are at 40 million people with FH worldwide, but most remain unrecognised and inadequately treated. To bridge this gap in coronary prevention several guidelines on detecting and managing FH have been published. We briefly review these and comment on the potential role of pharmacists in case detection, point-of-care testing and pharmacotherapy.
Literature
1.
Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4:214–25.PubMedCrossRef
2.
Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168:1–14.PubMedCrossRef
3.
Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J. 2008;337:a2423.CrossRef
4.
Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. Br Med J. 2000;321:148.CrossRef
5.
6.
Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolaemia. Atherosclerosis. 2004;173:55–68.PubMedCrossRef
7.
Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial hypercholesterolemia. J Clin Lipidol. 2011; 5:133–40.
8.
The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011; 28 Suppl 5:S213–S56.
9.
Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, et al. Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218:272–80.PubMedCrossRef
10.
Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011;12:221–63.PubMedCrossRef
11.
Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769–818.PubMedCrossRef
12.
Robinson JG, Goldberg AC. Treatment of adults with Familial Hypercholesterolaemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S18–29.PubMedCrossRef
13.
14.
Preiss D, Sattar N. Pharmacotherapy: statins and new-onset diabetes: the important questions. Nat Rev Cardiol. 2012;Advance online publication.
15.
Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198–208.PubMedCrossRef
16.
Simoens S, Foulon E, Dethier M, Mathieu C, Laekeman G. Promoting targeted screening for type 2 diabetes mellitus: the contribution of community pharmacists. Diabet Med. 2005;22:812–3.PubMedCrossRef
17.
Yamada C, Johnson JA, Robertson PP, Tsuyuki RT. Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Pharmacotherapy. 2005;25:110–5.PubMedCrossRef
18.
Smith JD, Battye K, Roufeil L, Mitchell C, White C, Veitch C, et al. Research to track the rural pharmacy workforce and identify the role that rural programs have on retention of the rural pharmacy workforce. In: Ageing DoHa, editor, Pharmacy Guild of Australia; 2010.
19.
Gerrald KR, Dixon DL, Barnette DJ, Williams VG. Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing. J Clin Lipidol. 2010;4:120–5.PubMedCrossRef
20.
Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10:2973–85.PubMedCrossRef
21.
Castelino RL, Bajorek BV, Chen TC. Are interventions recommended by pharmacists during home medicines review evidence-based? J Eval Clin Practi. 2010;17:104–10.CrossRef
22.
Cottin SC, Saunders TA, Hall WL. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc. 2011;70:215–31.PubMedCrossRef
23.
Charrois TC, Zolezzi M, Koshman L, Pearson SL, Makowsky G, Durec M, et al. A systematic review of the evidence for pharmacist care of patients with dyslipidaemia. Pharmacotherapy. J Human Pharmacol Drug Therapy. 2012;32:222–33.
24.
George J, McCaig DJ, Bond CM, Cunningham IS, Diack HL, Watson AM, Stewart DC. Supplementary prescribing: early experiences of pharmacists in Great Britain. Ann Pharmacotherapy. 2006;40:1843–50.CrossRef
25.
Block R, Pearson T. Organizing services for cardiovascular prevention. Curr Treat Options Cardiovasc Med. 2007;9:278–86.PubMedCrossRef
26.
Metadata
Title
Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?
Authors
Ines Krass
Adrian T. Walker
Gerald F. Watts
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 4/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9646-y

Other articles of this Issue 4/2012

International Journal of Clinical Pharmacy 4/2012 Go to the issue

Research Article

Factors associated with potentially inappropriate medication use by the elderly in the Brazilian primary care setting

Commentary

WHO guidelines for treatment of tuberculosis: the missing links

Research Article

Analysis of medication information exchange at discharge from a Dutch hospital

Research Article

Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea

Case Report

Successful treatment of sick sinus syndrome with Traditional Chinese Medicine

Research Article

Exploring patients’ motivation to participate in Australia’s Home Medicines Review program
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits